Stock CPH CIPHER PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Cipher Pharmaceuticals Inc.

Equities

CPH

CA17253X1050

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-04-23 pm EDT 		5-day change 1st Jan Change
8.81 CAD +5.01% Intraday chart for Cipher Pharmaceuticals Inc. -1.12% +59.03%
Mar. 15 Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024
Mar. 14 Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023. CI

Business Summary

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

Number of employees: 5

Sales per Business

CAD in Million2022Weight2023Weight Delta
Specialty Pharmaceuticals
100.0 %
27 100.0 % 29 100.0 % +6.12%

Sales per region

CAD in Million2022Weight2023Weight Delta
Canada
60.0 %
16 60.0 % 17 60.0 % +6.12%
United States
40.0 %
11 40.0 % 11 40.0 % +6.12%

Managers

Managers TitleAgeSince
Craig Mull CEO
 Chief Executive Officer - 19-03-25
Bryan Jacobs DFI
 Director of Finance/CFO - 22-08-14
James Bowen IRC
 Investor Relations Contact - -
Emilio Presti SAM
 Sales & Marketing - -
Diane Gajewczyk PRN
 Corporate Officer/Principal - 18-06-04

Members of the board

Members of the board TitleAgeSince
Harold Wolkin BRD
 Director/Board Member 72 16-08-07
Douglas N. Deeth BRD
 Director/Board Member 76 23-06-20
Craig Mull CEO
 Chief Executive Officer - 19-03-25
Hubert Walinski BRD
 Director/Board Member - 23-06-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 24,107,316 13,376,443 ( 55.49 %) 0 55.49 %

Shareholders

NameEquities%Valuation
Craig Mull
42.82 %
10,285,285 42.82 % 68 M $
Harold Wolkin
1.516 %
364,288 1.516 % 2 M $
Arthur M. Deboeck
1.047 %
251,540 1.047 % 2 M $
Christian Godin
0.3818 %
91,710 0.3818 % 604 461 $
Diane Gajewczyk
0.3498 %
84,036 0.3498 % 553 881 $
Highstreet Asset Management, Inc.
0.0787 %
18,900 0.0787 % 124 570 $
Front Street Investment Management, Inc.
0.0758 %
18,200 0.0758 % 119 956 $
Maxam Capital Management Ltd.
0.0624 %
15,000 0.0624 % 98 865 $
StoneCastle Investment Management, Inc.
0.0620 %
14,900 0.0620 % 98 206 $
Dimensional Fund Advisors Ltd.
0.0244 %
5,856 0.0244 % 38 597 $

Company contact information

Cipher Pharmaceuticals, Inc.

5750 Explorer Drive Suite 404

L4W 0A9, Mississauga

+905-602-5840

http://www.cipherpharma.com
address Cipher Pharmaceuticals Inc.(CPH)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Cipher Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.81 CAD
Average target price
7.617 CAD
Spread / Average Target
-13.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CIPHER PHARMACEUTICALS INC. Stock Cipher Pharmaceuticals Inc.
+59.03% 155M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.92% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.30% 570B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.59% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.38% 321B
ABBVIE INC. Stock AbbVie Inc.
+9.39% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.49% 217B
NOVARTIS AG Stock Novartis AG
+5.59% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-8.30% 204B
PFIZER, INC. Stock Pfizer, Inc.
-8.58% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CPH Stock
  4. Company Cipher Pharmaceuticals Inc.